

The Eurasia Proceedings of Health, Environment and Life Sciences (EPHELS), 2022

Volume 7, Pages 26-29

ICMeHeS 2022: International Conference on Medical and Health Sciences

Intracardiac Thrombi as a New Variant Cardiovascular Injury in a Previously Healthy COVID-19 Child: Case Report and Follow Up

Natalya KUKHTINOVA

Novosibirsk State Medical University

Sergey IVANOV

Meshalkin's National Research Center

Abstract: However, with the onset of the second COVID-19 pandemic wave, single cases of acute thrombotic complications in previously healthy children began to appear. Here we describe the patient with COVID-19 time related acute intracardiac thrombus in a previously healthy 6 year old girl. The treatment according to the national pediatric protocol, included low-molecular weight heparin infusion, high-dose aspirin, methylprednisolone, and intravenous immunoglobulin was lead to dissolving without cardiac surgery. A follow up after 12 months from discharge demonstrated: physical exam, ECG, echocardiography are all normal. Our case presentation shows, that all health care providers must be informed about the full range of complications and even a mild onset of COVID-19 in children.

Keywords: Intracardiac thrombi, COVID-19, Children

Introduction

Pediatric multisystem inflammatory syndrome is the most well-known variant of cardiovascular involvement (CVI) COVID-19 in children with an estimated incidence of approximately 0.2%-0.6% among pediatric SARS-CoV-2 infections. Along with this, myocarditis, pulmonary hypertension and cardiac arrythmias have reported as types of heart injury. However, with the onset of the second pandemic wave, single cases of acute thrombotic complications in previously healthy children began to appear.

Method

Here we describe the patient with COVID-19 time related acute intracardiac thrombus.

Results and Discussion

A previously healthy 6-year old girl of Caucasian ethnicity, admitted to the Cardiology Department of a Pediatric Hospital with a fever (40,0°C), tachycardia (PR 135), and severe headache two weeks after SARS-CoV-2 PCR positive acute respiratory infection. Past medical history of the patient revealed no evidence of heart disease or coagulopathy. On the day of admission, ECG-sinus tachycardia, echocardiography showed LVEF of 67%, mild RA enlargement and homogenus mass in RA 1,68x1,68x1,9 sm large. MRT confirmed right atrial thrombus without flotation (Figure 1).

The treatment according to the national pediatric protocol, included low-molecular weight heparin infusion, high-dose aspirin, methylprednisolone, and intravenous immunoglobulin was started. With treatment, her condition improved and the thrombus started dissolving without cardiac surgery. The patient was discharged

⁻ This is an Open Access article distributed under the terms of the Creative Commons Attribution-Noncommercial 4.0 Unported License, permitting all non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

⁻ Selection and peer-review under responsibility of the Organizing Committee of the Conference

from the hospital with a recommendation of long-term anticoagulant therapy with apixaban. After one month a follow up showed: hetrogenous masses reduced 1,3x0,74 sm large (Figure 2).




Figure 1. MRI showing the inmobile thrombus attached to the anterior right atrium wall




Figure 2. Echocardiography 1 month follow up had showing the size and density echogenic mass reduction

The three month follow up showed: no intracardiac echogenic mass visualized on transthoracic echocardiography. A follow up after 12 months from discharge demonstrated: physical exam, ECG, echocardiography are all normal (Table 1).

Table 1. Biomarkers regarding inflammation, coagulation, and cardiac injury

	Day 1	Day10	1 Month	3 Month
WCC (×109)	7.2	14.0	7.1	5.9
Lymphocytes (×109)	4.3	10.0	15.9	20,0
Hemoglobin (g/L)	97	115	126	127
Platelets (×109)	680	497	206	223
Fibrinogen (g/L)	N/A	3.0	N/A	N/A
D-dimers (ng/mL)	N/A	166.4	0,55	N/A
INR (ratio)	1.3	1.0	1.23	N/A
APTT (sec)	45.0	24.2	15.9	N/A
Pro-BNP (ng/L)	120,1	22,7	2,2	N/A
Troponin T (ng/L)	N/A	249	N/A	N/A
CRP (mg/L)	265	75.3	3,2	2
Procalcitonin (μg/L)	<100	<100	N/A	N/A

Conclusion

SARS-CoV-2 pathogenetic mechanisms in are still to be researched and the risk factors of CVI in children are unknown. Our case presentation clearly shows, that all health care providers must be informed about the full range of complications and even a mild onset of COVID-19 in children. Acute thrombotic complications, are probably, completely reversible conditions in previously healthy children. The systematic follow-up of pediatric COVID-19 patients, prospective cohort studies, ideally, prospective randomized controlled trials can aid us in our ability to stratify the risk and find potential therapeutic approaches.

Scientific Ethics Declaration

The author declares that the scientific ethical and legal responsibility of this article published in EPHELS journal belongs to the author.

Acknowledgements or Notes

* This article was presented as an oral presentation at the International Conference on Medical and Health Sciences (www.icmehes.net) held in Antalya/Turkey on November 17-20, 2022.

References

- Berthelot, J.M., Drouet, L., & Lioté, F. (2020). Kawasaki-like diseases and thrombotic coagulopathy in COVID-19: Delayed over-activation of the STING pathway? *Emerging Microbes Infections*, 9(1), 1514-1522
- Bigdelian, H., Sedighi, M., Sabri, M.R., Dehghan, B., Mahdavi, C., Ahmadi, A, Ghaderian, M., Rahimi, H., Sadeghizadeh, A., Emadoleslami, M., Mostafavi, S.N., Saleh, R., Javadi, N., Derakhshan, M., Pourmoghaddas, Z., & Sarfarazi Moghadam, S. (2021). Case report: Acute intracardiac thrombosis in children with coronavirus disease 2019 (COVID-19). *Frontiers in Pediatric*, 9.
- Chartier, L., Béra, J., Delomez, M., Asseman, P., Beregi, J. P., Bauchart, J.J., Warembourg, H., & Théry, C. (1999). Free-floating thrombi in the right heart: diagnosis, management, and prognostic indexes in 38 consecutive patients. *Circulation*, *99*(21), 2779–2783.
- Koçak, G., Ergül, Y., Nişli, K., Hatemi, A. C., Tutar, E., Tokel, K., & Çelebi, A. (2020). Evaluation and follow-up of pediatric COVID-19 in terms of cardiac involvement. A scientific statement from the association of Turkish pediatric cardiology and pediatric cardiac surgery. *Anatolian Journal of Cardiology*, 24(1),13-18

- Minen, F., Hands, C., Mustafa, M.R, Pienaar, A., & Lillie, J. (2019). Thrombophilia in pediatric patients with multisystem inflammatory syndrome in children secondary to Coronavirus disease 2019 supported on extracorporeal membrane oxygenation. *ASAIO Journal*, *67*(1), 7–11.
- Patel, M., Wei, X., Weigel, K., Gertz, Z.M., Kron, J., Robinson, A.A., & Trankle, C.R. (2021). Diagnosis and treatment of intracardiac thrombus. *J Cardiovasc Pharmacol*, 78(3), 361-371.
- Rodriguez Gonzalez, M., Castellano Martinez, A., Cascales Poyatos, H. M., & Perez Reviriego, A.A. (2020). Cardiovascular impact of COVID-19 with a focus on children: *A systematic review. World Journal of Clinical Cases*, 8(21), 5250-5283.
- Saed Aldien, A., Ganesan, G.S., Wahbeh, F., Al Nassr, N., Altarahwneh, H., Al Theyab, L., Saed Aldien, S., Tomerak, S., Naveed, H., Elshazly, M. B., & Zakaria, D. (2022). Systemic inflammation may induce cardiac injury in COVID-19 patients including children and adolescents. Cardiovascular Revascularization Medicine: Including Molecular Interventions, 35, 169-178.
- Schroder, J., Lund, M., Vejlstrup, N., Juul, K., & Nygaard, U. (2021). Left ventricular thrombus in multisystem inflammatory syndrome in children associated with COVID-19. *Cardiology in the Young, 32*(1),138-141.

Author Information			
Natalya Kukhtinova	Sergey Ivanov		
Novosibirsk State Medical University	Meshalkin's National Research Center		
Novosibirsk, Russia	Novosibirsk, Russia		
Contact e-mail: natalya_kuhtinov@mail.ru			

To cite this article:

Kukhtinova, N.V. & Ivanov, S.N. (2022). Intracardiac thrombi as a new variant cardiovascular injury in a previously healthy COVID-19 child: Case report and follow up. *The Eurasia Proceedings of Health, Environment and Life Sciences (EPHELS)*, 7, 26-29.